Injective's upcoming Altria Mainnet upgrade and the filing of an INJ-based ETF by 21Shares have increased market optimism. The protocol is positioned on a strong multi-year support zone with rising institutional interest, developer activity, and transaction volume signaling potential growth and recovery to price targets around $21 and longer-term forecasts up to $40-$44.@Injective #Injective $INJ